# Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease

**Authors:** Jieling Xiao, Lincoln Kai En Lim, Cheng Han Ng, Darren Jun Hao Tan, Wen Hui Lim, Cyrus S. H. Ho, Eunice Xiang Xuan Tan, Arun J. Sanyal, Mark D. Muthiah

PMC · DOI: 10.3389/fmed.2021.691696 · Frontiers in Medicine · 2021-06-30

## TL;DR

This study finds a strong link between fatty liver disease and depression, showing higher depression rates in patients with non-alcoholic steatohepatitis.

## Contribution

The study provides a meta-analysis showing a significant association between NAFLD/NASH and depression, identifying key risk factors.

## Key findings

- Depression prevalence is 18.21% in NAFLD patients and 40.68% in NASH patients.
- NAFLD increases the risk of depression (OR: 1.29), and NASH patients have a higher risk (RR: 2.83).
- Risk factors include diabetes, high BMI, female sex, smoking, and lung disease history.

## Abstract

Background and Aims: Both non-alcoholic fatty liver disease (NAFLD) and depression have a high global prevalence which is projected to increase further. While studies exploring the association have been done, there are conflicting data. This study aims to assess the prevalence and association between depression and NAFLD.

Methods: Medline and Embase were searched from inception to March 3, 2020. Meta-analysis of proportions using the generalized linear mix model was conducted to analyze the pooled prevalence of depression in NAFLD patients. Risk factors for depression in NAFLD patients were evaluated in conventional pairwise meta-analysis.

Results: Ten studies involving 2,041,752 NAFLD patients were included. Pooled prevalence of depression was 18.21% (CI: 11.12–28.38%) in patients with NAFLD and 40.68% (CI: 25.11–58.37%) in patients with non-alcoholic steatohepatitis (NASH). NAFLD resulted in significantly higher risk of development of depression (OR: 1.29, CI: 1.02–1.64, p = 0.03). NASH patients had a significantly higher risk of depression compared with NAFLD patients (RR: 2.83, CI: 2.41–3.32, p < 0.001). Diabetes, body mass index (BMI), female sex, smoking, and history of pulmonary disease were significant risk factors for depression in NAFLD patients.

Conclusion: This study demonstrated a high prevalence of depression in NAFLD patients and a significant association between both conditions. Furthermore, patients with NASH had a significantly higher risk of depression compared with those with NAFLD. Diabetes, BMI, history of lung disease or smoking, and female gender were significant risk factors. Further studies investigating the pathophysiological mechanism underlying depression and NAFLD are needed.

## Linked entities

- **Diseases:** non-alcoholic fatty liver disease (MONDO:0013209), depression (MONDO:0002050), non-alcoholic steatohepatitis (MONDO:0007027), diabetes (MONDO:0005015), pulmonary disease (MONDO:0005275)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}
- **Diseases:** metabolic syndrome (MESH:D024821), Fatty Liver (MESH:D005234), chronic (MESH:D002908), lung disease (MESH:D008171), weight gain (MESH:D015430), obese (MESH:D009765), mood disorders (MESH:D019964), hypertension (MESH:D006973), cardiovascular diseases (MESH:D002318), DSM-IV (MESH:D006011), heart diseases (MESH:D006331), Depression (MESH:D003866), Anxiety (MESH:D001007), hyperlipidemia (MESH:D006949), systemic (MESH:D015619), neurologic disease (MESH:D020271), addiction (MESH:D019966), alcohol (MESH:D000437), type 1 and type 2 diabetics (MESH:D003924), NASH (MESH:D005235), smoking (MESH:D015208), inflammation (MESH:D007249), COPD (MESH:D029424), weight loss (MESH:D015431), Diabetes (MESH:D003920), NAFLD (MESH:D065626), Mental Disorders (MESH:D001523), MDD (MESH:D003865), fibrosis (MESH:D005355), CES-D (MESH:C538175), binge eating (MESH:D002032), chronic liver disease (MESH:D008107), cancer (MESH:D009369), asthma (MESH:D001249)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8278401/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8278401/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC8278401/full.md

---
Source: https://tomesphere.com/paper/PMC8278401